news @ Unravel Bio
|
Unravel Biosciences received grant to support neurodegenerative target discovery
March 29, 2023 Award from MGH CCXDP advances effort to identify new treatments for X-linked dystonia Parkinsonism (XDP) |
RVL001 |
Unravel announces positive feedback to FDA pre-IND meeting
February 15, 2023 FDA pre-IND feedback provides a clear path forward to initiate proof-of-concept clinical study of RVL001 in Rett Syndrome patients later this year |
|
Unravel partners with Spanios Lab to identify novel targets for rare cancer
November 8, 2022 Synergy between Unravel's probabilistic network model of human health and Spanios' patient-derived tumor organoids will unlock a path to efficient discovery of therapeutic targets for rare cancers. |
|
Unravel licenses Wyss Institute at Harvard's technology platform to accelerate CNS drug discovery
September 27, 2022 Unravel has exclusively licensed a patent for treating Rett syndrome and CKDL5 deficiency disorder along with cutting edge CogniXense cognitive screening technology, built on years of DARPA funding. This license will enable Unravel to progress to clinical stage and expand its asset portfolio for indications beyond Rett syndrome. |
|
Unravel partners with TMA Precision Health to advance Rett syndrome therapy to the clinic
July 5, 2022 Unravel has partnered with TMA Precision Health to accelerate clinical translation of its proprietary orla liquid therapeutic for Rett syndrome. |
|
RTK Group announces investment in Unravel Biosciences
June 14, 2022 Expands RTK Group's biopharma investment portfolio into startups developing platform technologies having high potential for disruptive innovation and brings Unravel's innovative patient stratification approach to the forefront of therapeutics discovery. |